Ignite Creation Date:
2024-05-06 @ 8:25 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06376084
Status:
RECRUITING
Last Update Posted:
2024-04-19
First Post:
2024-04-17
Brief Title:
Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
Osimertinib With Chemotherapy as First-line Therapy for Patients With Locally Advanced or Metastatic Epidermal Growth Factor Receptor EGFR Mutation-positive Non-Small Cell Lung Cancer NSCLC A Multicentre Observational Study FOREFRONT
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
FOREFRONT
Brief Summary:
To estimate parameters related to clinical outcomes in a real-world seeting including investigator reported PFS and OS
Detailed Description:
The objectives of this study are to assess the effectiveness and safety of Osimertinib combined with chemotherapy in a real-world setting in patients with locally advanced or metastatic EGFR mutation-positive NSCLC
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None